Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. VICTOZA
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

VICTOZA

Medicine - Posted on Aug 26 2021
Active substance (DCI)
  • liraglutide
history (6)
  • 7/30/21

    VICTOZA (liraglutide)

    Key points The Committee reassessed nine proprietary medicinal products, including two fixed-dose combinations with insulins...
    CAV :
    54321
    icône flèche
  • Economic analysis
    12/5/18

    VICTOZA (liraglutide)

    VICTOZA (liraglutide)
    CAV :
    54321
    icône flèche
  • 9/7/16

    VICTOZA (liraglutide)

    Le laboratoire ne demande pas le remboursement en monothérapie
    icône flèche
  • 3/18/15

    VICTOZA (liraglutide), antidiabetic

    No clinical benefit demonstrated in the management of patients with type 2 diabetes in triple therapy No role in the therape...
    CAV :
    54321
    icône flèche
  • 4/15/15

    VICTOZA (liraglutide)

    VICTOZA (liraglutide)
    CAV :
    54321
    icône flèche
  • 12/2/09

    VICTOZA

    Progrès thérapeutique mineur dans le traitement du diabète de type 2 VICTOZA est indiqué dans le traitement du diabète de ty...
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • A10BJ02
Manufacturer
NOVO NORDISK
Presentation

VICTOZA 6 mg/ml, solution injectable en stylo prérempli

Boîte de 2 stylos de 3 ml - Code CIP : 396 323-6

VICTOZA 6 mg/ml, solution injectable en stylo prérempli (code CIS : 62645506)

2 cartouche(s) en verre dans stylo pré-rempli de 3 ml - Code CIP : 3400939632360

All our publications
    Diabetes mellitus Drug therapy Kidney diseases

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
WFTmr0Bek5YHTKss